ATC Group: L04AB04 Adalimumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AB04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
5 L04AB04 Adalimumab

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 2.9 mg

Active ingredients in L04AB04

Active Ingredient Description
Adalimumab

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).

Related product monographs

Title Information Source Document Type  
HUKYNDRA 40mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
HUKYNDRA 80mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 20mg Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 40mg/0.4ml Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 40mg/0.8ml Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 40mg/0.8ml Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 80mg Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
IDACIO Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LIBMYRIS 40 mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
LIBMYRIS 80 mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
YUFLYMA 40 mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Albania (AL)

Canada (CA)

Hong Kong (HK)

Japan (JP)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.